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Comparative efficacies of Calmare® therapy and transcutaneous
electrical nerve stimulation in randomized peripheral neuropathy
subjects with resting state fMRI monitoring
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Abstract: Clinical reports of Calmare® protocol efficacy suggest enhanced durability
compared to TENS and the possibility changes in resting fMRI connectivity. The objective
was to compare peripheral neuropathy pain relief and resting fMRI changes with Calmare
and TENS treatments. Randomized double-blind trials performed in August 2015 and
between August 2016 and November 2017, with 18 and 20 human peripheral neuropathy
subjects, respectively. The initial trial examined effects of a single session while the latter
trial examined the effects of a course of ten treatment sessions on consecutive weekdays.
fMRI scans were examined for changes in blood flow correlations and connectivity.
Subjective pain scores were similarly reduced by both Calmare and TENS treatments. In
the ten-session study, the relief was prolonged, again similarly for both groups. The pain
area relieved, which may be a more important metric than residual pain score, was reduced
significantly more in the Calmare group than in the TENS group in post hoc analysis. After
treatment, resting fMRI showed an increase in global efficiency and in correlation of
activity between left hippocampus and right amygdala for both treatment modalities.
Treatment with Calmare or TENS yields prolonged pain reduction and correlates with
reproducible fMRI changes.
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Introduction

Multiple studies have shown that transcutaneous electrical nerve stimulation (TENS)
effectively reduces hyperalgesia and allodynia in neuropathy patients (1,2) as well as
subjects with spinal cord injury (3,4). Scrambler therapy, using the Calmare® device
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(Calmare Therapeutics Inc, Fairfield, CT, USA) and referred to here as Calmare treatment,
is a transcutaneous electrical treatment that has also demonstrated significant ability to
alleviate neuropathic pain according to one review (5). Subsequently, reduction of chronic
post-mastectomy pain (6) and chemotherapy-induced peripheral neuropathy (CIPN) (7-9),
and neuromyelitis optica (10) were also reported with Calmare. However, to our
knowledge, no reports of efficacy comparison between Calmare and TENS nor of fMRI
correlates of pain reduction have been published.
We evaluated whether Calmare efficacy was greater or more durable than TENS in
subjects with peripheral neuropathy. Randomized prospective double-blind studies of onesession and ten-session treatment regimens were conducted with resting state fMRI before
and after treatment periods and upon later return. Subjects scored their burning superficial
pain, which, together with paresthesia and numbness, is a common symptom in peripheral
neuropathy (11,12).
The neural network that processes acute pain includes regions of the insular,
secondary somatosensory, and anterior cingulate cortices, as well as thalamus, and
hypothalamus (13). There is less consensus on brain regions involved with chronic pain.
One metastudy found that low back pain, post-herpetic neuralgia, and osteo-arthritic knee
pain have different fMRI signatures in spontaneous and evoked pain paradigms (14).
Similarly, gray-matter volumes change differentially in chronic back pain, complex
regional pain syndrome, and knee osteoarthritis (15). Nevertheless, fMRI with chronic pain
often shows aberrant connectivity involving the anterior cingulate gyrus, insula, medial
prefrontal cortex, precuneus, amygdala, striatum, hippocampus, thalamus, tegmentum,
nucleus accumbens, and periaqueductal gray (16-22). Placebo and sham effects are wellknown to affect perception of acute (23) and chronic (24) pain and central mechanisms
mediating placebo effects have been hypothesized (25-27). Here, we take advantage of
analgesia from Calmare and TENS to examine changes in resting state network activation
for idiopathic peripheral neuropathy subjects.

Methods

Subject selection: Subject anonymity was protected by the protocol reviewed and approved
by the Brigham Young University Internal Review Board, Protocol F15130 and registered
as NCT04242797 at clinicaltrials.gov. Eighteen subjects for the one-session study and
twenty for the ten-session study were chosen from a pool of interested candidates with
chronic pain conditions and gave written informed consent (see figure 1). Sample size for
the ten-session study was based on treatment efficacy observations from the one-session
study. Inclusion criteria included a diagnosis by a medical doctor of peripheral neuropathy,
preferably idiopathic, a pain rating higher than 4 (on a scale of 1-10), and minimal
medication history subject to exclusion criteria (see table S1). Candidates taking
pregabalin, topiramate, gabapentin or tramadol were asked to consult with their physician
prior to discontinuing the medications two weeks before the study to reduce medication
variability and because they are suspected to inhibit Calmare efficacy. They were not
excluded from the trial if they were unable, such that a few subjects were included who
took these medications up to a few days before beginning the study and, in one case, during
the study. Subjects were assigned to groups by the blind-manager for each study using a
random number generator and an algorithm to assign similar gender blocks for each
treatment block, and assignments were well-matched between groups for their gender, age,
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diagnosis, and drug history (see tables S1 and S2). Pain was most frequently described as
burning and sharp, starting in the feet, and moving proximally as the disease progressed.
This manuscript adheres to Consort 2010 guidelines.
Study protocols: In the one-session study, the subjects received an initial fMRI, the doubleblind treatment, and a second fMRI on day one, then returned for a third fMRI on day two.
The nine subjects in the TENS group were invited two weeks later for a non-blind Calmare
treatment as a crossover group. Seven did so and were treated identically to the original
two groups except for the elimination of the blind. In the ten-session study, the subjects
received an fMRI followed by treatment on day one, treatment only on days two through
nine, then treatment followed by an fMRI on day 10. They were scheduled to return for a
third fMRI approximately six weeks from the second fMRI. Two subjects were completely
relieved of pain before the end of the set of 10 treatments. They were not treated further
and did not experience a return of pain before day 10. They also received the second fMRI
on day 10. Subjects in the ten-session study were interviewed by phone approximately 12
weeks after the end of treatment (~6 weeks after the third fMRI) about the overall results
of the study.
Nerve stimulations instrumentation characteristics: Treatments were administered using a
Calmare (Model MC-5A, Competitive Technologies Inc., Seoul, Korea) with two TENS
(TENS7000, Current Solutions, LLC, Austin, Texas) units mounted to it on a plexiglass
frame (see figure S1). The amplitude knobs of the TENS units were ganged with those of
the Calmare with O-rings and the outputs selected under Bluetooth control (see figure S2).
The TENS unit continuously generates rectangular, unidirectional 300 µs-wide pulses at
43 Hz. The Calmare unit generates distorted sine waves (see figure S3) with a base
frequency varying between 46 and 56 Hz from one random duration period (RDP) to the
next, and harmonics that vary in intensity from one RDP to the next (see figure S4). The
harmonics distort the sine wave, and the variation in base frequency and harmonic
intensities assure that the distortion changes from one RDP to the next. The RDPs lasted
~2 s on average.
Double-blind management and treatment protocol: Subjects were randomly assigned to
therapy groups and the instrument switch was set for each subject by the double-blind
supervisor (see figure S1). The therapist applied the electrodes proximal to the affected
area on the seated subject, typically with a pair on each affected limb, and raised the signal
amplitude by turning the ganged knob for each lead pair. Subjects were asked to report the
level of pain relief as the amplitude was increased to an optimal level. Sometimes the
electrodes or the amplitude were further adjusted during the 30-minute treatment period.
Subjects rated their pre- and post-treatment pain apart from the therapist either in writing
(preliminary study) or using a laptop (ten-session study) using the Washington Neuropathic
Pain Scale (WNPS) (11,12) and the Visual Analog Scale (VAS) (28) each day of treatment,
with superficial burning pain reduction pre-specified as the primary outcome. Following
therapy, the therapist took notes on electrode placement, area in pain, and other
observations.
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Post-treatment MRI and follow-up: The subjects returned after one day (one-session study)
or approximately six weeks (ten-session study) and again rated their pain using the WNPS
and VAS and had MRI scans. In the ten-session study, subjects were also called ~12 weeks
after the therapy to verbally rate their pain with the WNPS and other follow-up qualitative
questions about the duration of effects, feedback for the study, life events that may have
affected the study, and their guess regarding their modality group assignment.
MRI scan parameters: All MRI scans were performed on a Siemens 3T Tim Trio scanner
with a 32-channel head coil at the BYU MRI Research Facility. Structural images were
acquired using a T1-weighted MPRAGE sequence with the following parameters: TR = 20
ms, TE = 4.92 ms, slices = 192 interleaved, voxel size = 1.0 × 1.0 × 1.0 mm, FOV = 256
mm, flip angle = 25°, total acquisition time = 8:55 min. Resting state BOLD data were
acquired using a multi-band EPI sequence with the following parameters: multi-band factor
= 8, TR = 867 ms (1125 TRs), TE = 44.2 ms, slices = 72 interleaved, voxel size = 2 × 2 ×
2 mm, FOV = 208 mm, flip angle = 52°, total acquisition time = 12:06 min. The first five
volumes acquired were discarded to allow for T1 equilibration.
MRI data preprocessing: Preprocessing was performed using the Analysis of Functional
Neuroimages (AFNI) suite of programs and Advanced Normalization Tools (ANTs)
(29,30). The following steps were performed: 1) structural and functional image coregistration, 2) de-spiking, 3) motion correction by censoring of image in which there was
a significant motion event (>.5 mm translation), 4) noise regression of a) white matter, b)
CSF, and c) motion-related noise. Cleaned fMRI time series were segmented according to
the Automated Anatomical Labeling Atlas (31) as updated with additional subdivisions of
the orbitofrontal cortex, AAL2, (32) after which the 94 region-of-interest (ROI) time
signals were averaged within regions and correlated between regions for the creation of a
scan-specific correlation matrix.
Analysis of subjective pain reports: Student’s t-tests were performed on treatment group
averaged VAS and WNPS pain scores. Also, three lines of evidence were combined to
assess the pained areas post hoc using the definitions in Table 1: 1) patient drawings on the
initial interview, 2) therapist drawings at the beginning of treatment sessions, and 3)
electrode positioning notes by the therapist. These were used for comparison of proportions
and odds-ratio hypothesis testing (details in Supplemental Data: Statistical Methods). To
reduce the likelihood of false positive findings due to multiple comparisons, statistical
significance for a given test was only considered relevant if it appeared in at least four of
the five groups.
Objective fMRI pain analysis methods (correlation and graph theory analysis): Weighted
correlation matrices were produced by correlating the time courses of all pairs of ROIs. For
statistical tests performed on these raw correlation matrices, Fisher’s R-to-Z transformation
was first applied. Then, the treatment effects on ROI-pairing functional connectivity were
examined. A subset of 13 paired ROIs commonly implicated in chronic pain, i.e. superior
medial prefrontal cortex, orbital medial prefrontal cortex, insula, anterior cingulate gyrus,
middle cingulate gyrus, posterior cingulate gyrus, hippocampus, amygdala, precuneus,
caudate, putamen, globus pallidum, and thalamus, with n x (n-1) / 2 = 325 correlations,
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was selected for analysis. As pain score changes were largest between scans 1
(pretreatment) and 2 (post treatment in the first study, and post final treatment in the second
study), we focused on treatment effects from scan 1 to 2. We performed paired T-tests of
treatment effect on the correlation coefficient for each treatment group (Calmare vs TENS
vs crossover in the first study; Calmare vs TENS in the second study). Results were
considered relevant when the P value was below 0.05 for a given pairing in multiple groups,
again out of consideration for possible false positives in any given test in a single group.
Additionally, we examined treatment effects on network properties of subject brain
correlation-coefficient graphs (i.e. sets of linked nodes, where the nodes are ROIs and the
links are correlation coefficients across scans). Weighted correlation matrices were given
a threshold at 10% sparsity. Graph measures of connectivity were taken from the Brain
Connectivity Toolbox (33) and were implemented in MATLAB (MathWorks Inc, Natick,
MA). For each scan, the global efficiency and global modularity were calculated. Then, for
each ROI within each scan, the regional metrics of clustering coefficient, degree, and
betweenness centrality were determined. Treatment effects on global graph metrics were
examined with paired T-tests between scans 1 and 2 in both studies with a significance
level set at α=0.95. Graph metrics with significant changes from scan 1 to scan 2 were
further examined in a linear mixed-effects regression (the R language LME4 package) as
predictors of pain score. fMRI observables were pre-specified as secondary outcome
measures.

Results

Subjective pain score results: The group average VAS and WNPS residual pain scores were
substantially reduced relative to the initial scores after the ten-session treatment (see table
2). The two treatment modalities resulted in similar pain reductions for all pain types, with
hot and surface pain being the most reduced types. Average pain scores reported at six
weeks after the therapy remained reduced, especially for hot pain and surface pain in both
groups, but also for cold pain in the Calmare group and sharp pain and sensitivity in the
TENS group. No subject reported increased pain or other unintended effects.
The WNPS hot pain scores in the two studies (see figure 2), dropped significantly
(P<0.01) after the first treatment, with one exception (TENS in the one-session study).
There were also significant drops after the first treatment in the WNPS intense pain score
in the ten-session study and the VAS scores in both studies (see figures S5-S7). Pain
reductions were not significantly different between TENS and Calmare. The crossover
Calmare treatment during the one-session study also produced statistically significant
drops in both VAS (P<0.01) (see figure S6) and WNPS hot pain (P<0.01) (see figure 2C).
In the ten-session study, the WNPS hot pain scores dropped upon the first treatment
(see figure 2, D and E) and then stayed low for the ten-session period for both Calmare and
TENS treatments (see figure 3), with each treatment producing a small effect that was lost
by the next day. Both methods of treatment were also successful in reducing pain by the
final day (post 10) compared to day 1, (P<0.005). There was no significant difference
between Calmare and TENS in total pain reduction (Post 10 vs Pre 1, P> 0.05). The return
of pain at 6 weeks (pre W6) was modest, the same for the two groups (P>0.05).
Post hoc subjective pain region results: As shown in figure 4, the total numbers of painaffected regions (summed over all the subjects in a group) before the ten-session study
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were 80 (Calmare) and 51 (TENS). A comparison of proportions test showed the number
of pain areas was more effectively reduced by Calmare than by TENS (Z=3.19, p<0.005).
Using the same data set, the odds ratio test for treatment success (reduction in number of
pained areas to one or zero in a given quadrant) was 22.67 [95% CI 4.71 to 109], with
Calmare treatment more effective than TENS (P<0.0001).
fMRI results: T-tests on the Pearson’s R Correlation Coefficients, Fisher R-to-Z
transformed: The left hippocampus-right amygdala correlation was increased upon
treatment (P<0.05) in three of the groups, i.e. Calmare (0.015±0.13,n=9 to 0.23±0.22,n=9)
in the one-session study, and both TENS (0.047±0.13,n=8 to 0.25±0.18,n=8) and Calmare
(0.15±0.16,n=9 to 0.26±0.14,n=9) groups from the ten-session study, and increased but
possibly underpowered in the TENS one-session study (0.097±0.24,n=8 to 0.23±0.11,n=8,
P<0.1) and decreased slightly in the Crossover study (0.17±0.20,n=7 to 0.14±0.24,n=7,
P<0.3).
Graph theory analysis: No significant differences were observed in any regional graph
theory metrics from scan 1 to 2 in either study. We tested for changes in functional brain
graph global efficiency from scan 1 to 2. In the one-day study, the crossover group and all
groups when combined had increased global efficiency (p<0.05) after treatment. In the
two-week study, both treatment groups, when combined, also had significantly increased
global efficiency as a result of treatment (p<0.05). In a mixed effects model with global
efficiency as a fixed effect predictor of pain score and with subject ID included as a random
effect, we found that global efficiency significantly predicted neither VAS nor WNPS
intensity pain scores (p>0.05).
Evaluation of the blind: In a perfect blind, the subjects and therapists would predict the
assigned treatment group correctly 50% of the time. In the one-session study, 56% of the
subjects predicted correctly the day after the treatment along with 72% of the therapists. In
the ten-session study, the subjects were 83% correct after the treatments and 69% correct
12 weeks later, while the therapists were 94% correct after the treatments.

Discussion

To our knowledge, this is the first report of a Calmare study of peripheral neuropathy with
a double-blind, active TENS control. A similar randomized non-blind study using a TENS
control group was carried out during the same period as this study, which showed
superiority in Calmare treatment effects compared to TENS treatment effects (34). Here,
the Calmare was effective in reducing reported pain scores for a prolonged period in the
ten-session paradigm, as was TENS. Calmare was more effective in reducing the number
of pained areas. This is plausible because animal and human clinical studies (35) have
shown that high frequency (>100 Hz) and low frequency (<10 Hz) TENS have differential
effects on descending pain regulation pathways in the spinal cord, suggesting that a mix of
non-traditional frequencies, such as found in the Calmare harmonics, could optimize
efficacy.
The subject blind was moderately successful, but the therapist blind was quite
unsuccessful (see figure S1 for further discussion). In future studies, single-blind with
comparison of traditional TENS and Calmare would be equally successful and easier to
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administer. The recent study of neuromyelitis optica (10) compared Calmare to a vibrator
single-blind and showed significant effects of Calmare and no effect of the vibrator on
pain, with good statistical blinding of the subjects. The observation that traditional TENS
was equally effective at prolonged block of pain suggests that generic electrical nerve
stimulation, but not the vibratory nerve stimulation parameters used there, mediates the
pain relief.
In the fMRI studies, global efficiency and left-hippocampus/right-amygdala
correlations were increased by treatment. This neural correlate to decreased perception of
chronic pain can be interpreted in terms of the “learned pain” model, in which the central
circuits subserving acute pain are inappropriately prolonged by learning and memory based
in the hippocampus (14,20,36). These central circuits include both analytical localization
in the somatosensory cortex and affective evaluation in the limbic system (e.g. cingulate
gyrus and amygdala). With the expectation that the most likely treatment-effect changes in
central function would be in the limbic system (37), we initially searched for reduced
activity (blood flow) or connectivity (correlation in the time series of blood flow
fluctuations) in these regions. Because the subjective pain reports for the two Calmare, two
TENS and one crossover group were similar, we evaluated their fMRI results both
independently and jointly. As expected for resting fMRI, the blood flow variations were
not statistically significant, and the correlation coefficients showed many possible
statistically significant (at α=0.05) interactions between the 13 regions of interest, but none
except the left-hippocampus/right-amygdala increase was reproducible between the five
groups. The involvement of the amygdala may relate to the recent observation that the
mouse central amygdala contains GABAergic neurons that project to numerous pain
regions in the brain and inhibit pain-associated behaviors (38). Interestingly, the left
hippocampal morphology has been recently implicated in biasing memories of pain (39) in
ways that can affect personality-dependent placebo responses in chronic pain.
Nevertheless, the increased correlation between the left hippocampus and right amygdala
upon reduction of pain is difficult to rationalize both because of the contralateral
connection, which has no obvious direct neurological basis, and because one might expect
such an increase in correlation to subserve aberrant memory of pain, rather than a decrease
in pain. One is forced to speculate that the increased correlation in this particular circuit is
inhibitory rather than excitatory and of sufficient magnitude as to stand out. In an intraoperative corticocortical evoked potential study of medicinally intractable seizure patients,
stimulation of the left posterior hippocampus was found to produce recordable activity in
the right posterior cingulate gyrus and stimulation of the right posterior cingulate gyrus
produced recordable activity in the right amygdala (40). Perhaps this indirect (two-step)
connection between the left hippocampus and right amygdala, obscured by network
complexities, is responsible for the increased left hippocampus/right amygdala correlation
treatment effect reported here.
Regional network analysis using graph theory, in which each region of interest is
treated as a “node” and each pairwise correlation with 93 regions as a possible “edge,”
yielded no consistent change in any of the standard metrics (see methods). But global
efficiency, the connectivity of the global network, was increased after treatment for both
studies when the treatment groups were combined. This can be interpreted to suggest that
an individual in chronic pain reflexively shuts down many connections in the brain, perhaps
as one might expect for a defensive posture where the brain limits its interactions in
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negative feed-forward preparation for focal risks. Once the risk is perceived as resolved,
the brain returns to a more globally free interaction state where it monitors input in a nonselective fashion, prepared for any eventuality of environmental change. After therapy,
interactions between regional pairings deemed to be of lower priority for the focal risk are
disinhibited and global efficiency returns to a “broad environmental surveillance” state.
Correlations between the important limbic regions, the hippocampal “memory” region and
the amygdala “fear, reward learning, anxiety” region could reasonably be expected to
subserve the learned pain phenotype.
Both the pain and fMRI observations presented here involved multiple
measurements. In both cases, the reproducibility of uncorrected statistical significance for
given measures between similar groups (TENS and Calmare, one-session and first session
of the ten-session) is used as a measure of reliability. It was originally intended that the
fMRIs results from the one-session study would allow power estimates for the second
study, but ultimately it became expedient to proceed with the ten-session study before that
could be accomplished.
In future studies, perhaps connections with the localization regions responsive to
the individual subject’s specific pained areas (i.e. in “foot region” of the postcentral gyrus)
and/or with the error detection regions of the cingulate gyrus (41) could also be identified.
Normal (pain-free) treated controls would be valuable to distinguish pain reduction effects
from pain-unrelated treatment effects and a single-treatment paradigm would be sufficient.

Conclusions

In conclusion, Calmare and TENS both produced prolonged, substantial pain relief for
subjects with idiopathic peripheral neuropathy and fMRI showed increased correlations
between blood flow vacillations in left-hippocampus and right-amygdala as well as
increased global efficiency after a single treatment session and after a series of ten daily
treatments.
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Table 1. Definitions of pain areas
Pain Regionsa
Region 1
Region 2
Region 3
Region 4
Region 5
a

Lower Quadrants
Upper Quadrants
Toes and either tops or Fingers
bottoms of feet
Whole foot up to ankle
Whole hand up to wrist
Ankle to knee
Wrist to elbow
Knee to groin
Elbow
to
shoulder
dermatomes (C4-T3)
Superior to groin (left or right) Torso (left or right) except
shoulder dermatomes

A region was considered “in pain” if a subject reported pain in any portion of that region.
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Table 2. Average relativea pain remaining

VAS Pain
WNPS Intense Pain
WNPS Sharp Pain
WNPS Hot Pain
WNPS Dull Pain
WNPS Cold Pain
WNPS Sensitivity
WNPS Itchy Pain
WNPS Unpleasant Pain
WNPS Deep Pain
WNPS Surface Pain

Calmare
10 Day 6 Week
Tx
Return
38%
93%
35%
78%
31%
70%
30%
52%
51%
73%
28%
59%
35%
67%
61%
82%
43%
84%
39%
81%
30%
64%

TENS
10 Day 6 Week
Tx
Return
15%
69%
32%
66%
28%
53%
27%
48%
39%
70%
46%
61%
31%
57%
43%
81%
33%
71%
35%
78%
27%
56%

a

Average pain after ten-session therapy and upon follow-up 6 weeks later relative to the
original score. N=8-10 in each case (all subjects completed the initial surveys, but in some
cases one survey answer was missed at the end of treatments and two were missed at the
6-week return).
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Figure Legends
Figure 1. CONSORT 2010 Flow Diagram: Randomized clinical trial selection for both
the one-treatment and the ten-treatment study. The number of subjects in the two
studies are designated as one-session count + ten-session count where appropriate.
Of 376 subjects that volunteered for study in response to advertisements, the first 18
meeting the study criteria were selected for the preliminary one-treatment study,
nine randomly assigned to each group (Calmare vs. TENS). Seven of those assigned to
the TENS group opted to return three weeks later for unmasked Calmare treatment
as a crossover group. The following year, all of the original volunteers that were
qualified and had current contact information, except for the eighteen in the onetreatment study, were called back and invited to participate in the ten-treatment
study. The twenty that were qualified and willing were identified and randomly
assigned to each group (Calmare vs. TENS). Exclusions from the fMRI analysis were
due to data loss.
Figure 2. Upper: Average subject hot pain (WNPS) ratings for one-session study
before treatment (blue), after treatment (red), and next day (purple) for A) Calmare
group (N=9), B) TENS group (N=9), and C) Crossover group (N=7). Error bars are ±2
S.E.M. *P<0.01 (treatment effect, Post Tx vs Pre Tx, paired, one-tailed T test). Lower:
Average subject hot pain (WNPS) ratings for ten-session study before treatment 1
(after fMRI, blue), after treatment 1 (red), and (before treatment) next day (day 2,
purple) for D) Calmare group (N=10), E) TENS group (N=9). Error bars are ±2 S.E.M.
*P<0.01 (treatment effect, Post Tx vs Pre Tx, paired, one-tailed T test).
Figure 3. Average subject hot pain (WNPS) ratings for ten-session study before (pre)
and after (post) treatment each day and before fMRI at the 6-week post-treatment
follow-up for Calmare group (orange, N=8-10) and TENS group (blue, N=8-10).
Figure 4: The pre-treatment number of pained regions as compared to the posttreatment total for the Calmare group (red) and the TENS group (blue) in the tensession study.
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Excluded (n=336)
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Allocation
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Allocated to TENS (n=10+10)
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Follow-Up
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Statistical methods
Comparison of Proportions: For each group, the proportion of interest was defined as
the number of regions relieved of pain after treatment relative to the total number of
pained regions before treatment. The difference in the proportions of relieved pain
regions for the Calmare group (𝑃𝑃�1) and TENS group (𝑃𝑃�2 ) relative to the composite
standard error (which is based on the composite proportion of pained regions (𝑃𝑃�)
and the initial pain region counts for the Calmare group (n1) and the TENS group (n2))
was assumed to be Z distributed (Eq. 1) for the hypothesis test.
𝑍𝑍 =

(𝑝𝑝̅1 −𝑝𝑝̅2 )
1

(1)

1

�𝑝𝑝̅ (1−𝑝𝑝̅ )�𝑛𝑛 +𝑛𝑛 �
1
2

Odds Ratio: The treatment of each affected subject-quadrant (as defined in Table 1)
was determined to be “success” if only one region in the quadrant was still affected
post-treatment or the quadrant was completely pain free. Otherwise, the treatment
was classified as “failure.” The odds ratio (OR) is defined in Eq. 2 and its standard
error in Eq. 3 where a, b, c, and d represent Calmare “success” count, Calmare “failure”
count, TENS “success” count, and TENS “failure” count, respectively. Equation 4 gives
the 95% confidence interval for OR.
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆×𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹

𝑂𝑂𝑂𝑂 = 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹×𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
1

1

1

1

𝑆𝑆𝑆𝑆(𝑂𝑂𝑂𝑂) = �𝑎𝑎 + 𝑏𝑏 + 𝑐𝑐 + 𝑑𝑑

𝐶𝐶𝐶𝐶 ≡ 𝑒𝑒 (log(𝑂𝑂𝑂𝑂)±[1.96×𝑆𝑆𝑆𝑆(log(𝑂𝑂𝑂𝑂))])

(2)

(3)
(4)
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Figure S1. Assembled TENS/Calmare double-blind device. The two TENS units are
mounted on plexiglass above the Calmare. The white oval encompasses the O-ring
assembly that mechanically couples the amplitude control of the TENS to that of the
Calmare. The black box in front contains the Arduino-controlled switch for the output,
governing whether the TENS input or the Calmare input is put out. The two TENS
devices, each with two independent outputs (top) were modified to have output
amplitudes governed by one-turn potentiometers controlled by aluminum knobs. The
knobs were mounted on the plexiglass rack. The aluminum knobs were mechanically
coupled by O-rings to similar aluminum knobs, which, using set screws, replaced the
knobs on the Calmare. The output leads from the TENS and Calmare were both fed
into a black plexiglass box containing a Bluetooth receiver (Arduino UNO, Arduino,
Somerville, Massachusetts). The receiver was controlled by a computer kept out of
the treatment room, or out of sight in the treatment room, to switch all inputs from
either the Calmare or the TENS to the four outputs from the black box. Then, each of
the knobs was set at the counterclockwise extreme to eliminate any accumulation of
slippage of the O-rings between sessions. A trained therapist, blind to the treatment
group, then placed up to 4 electrode pairs on the subject’s skin proximal to the region
21

of pain. Generally, one pair was applied transversely to each leg or ankle. But in a few
cases of foot and hand neuropathy, additional pairs were applied to the wrists. Then,
while asking the subject about the level of sensation, the therapist or assistant would
turn up the amplitude slowly and gently until the subject reported feeling a mild
shock sensation, and then proceeded a bit further until the subject reported cessation
of the chronic pain, or until the knob reached its maximum position, which always
occurred below the muscle contraction induction level. As the therapist turned up a
Calmare knob, the TENS knob controlling the same output lead was rotated an equal
amount by the O-ring, producing a signal of similar amplitude, subjectively speaking,
whichever of the two modalities was being applied. This double-blind design benefits
from simplicity, but suffers from a few unavoidable tells that may become evident to
experienced therapists, but still could be easily hidden from subjects. The most
apparent tell is that the Calmare signal varies while TENS is steady, which therapists
may realize and subjects may inadvertently comment on during electrode placement.
A more subtle tell is that the Calmare instrument has, in addition to the broken circuit
fault detection, (which this design overcomes, see Figure S2), an undocumented
overdrive fault detection which causes it to enter into fault mode occasionally when
the amplitude knob is turned nearly all the way up. It seems to be related to circuit
resistance, as it seemed to occur more often with some types of electrodes than others
and could often be alleviated by replacing the electrodes. We inferred from this
behavior that it might be related to a feedback overdrive, such as might be used in a
current clamp configuration. The TENS instrument used does not have any fault
mode, so a knowledgeable technician might consciously or subconsciously associate
Calmare faults with a Calmare group assignment for a given subject.
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Figure S2. Switching circuitry diagram for assembled TENS/Calmare double blind
device. Leads from Calmare and TENS attached to Arduino Uno bluetooth receiver to
modulate output through standard electrode pads. The diagram shows the circuitry
for one of the four pairs of output leads, all four being controlled simultaneously by
the Arduino Uno. Each pair exits the black box in a single cable, which later bifurcates.
Circuitry in the switching circuit allowed for each of the four pairs of Calmare leads
to be connected through a 500-ohm resistor (simulating skin resistance) when out of
the circuit in order to bypass the Calmare broken-circuit detection warning and shutoff. Each input has an inductor connected to a flyback diode, which prevents sudden
spikes in voltage across the inductor with sudden interruptions or changes in current.
This allows the Arduino Uno to switch which treatment is being administered without
disconnecting either of the treatment inputs. The four output leads coming from the
black box (initial segments visible in the lower right of Figure S1) were Calmarebrand leads that had been cut, the back ends being inserted as inputs into the black
box. The leads were connected to standard electrode pads (Little PALS, Axelgaard
Manufacturing Company LTD, Fallbrooke, California) for application to healthy skin
regions in the affected limbs of the subjects.
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Figure S3. Oscilloscope reading of Calmare output over 0.5 seconds. Analyses of the
waveforms generated from the Calmare and TENS units were performed by directly
connecting the electrodes to the leads of a digital oscilloscope and spectrum analyzer
(Analog Discovery, Discovery Inc., Pullman, Washington). The Calmare output is a
randomly distorted sinusoidal curve in contrats to the TENS output, which consists
of rectangular pulses with a width of 300 µs initiated and followed by brief doubleexponential spikes (not shown) that appear to be designed for charging skin
capacitance, such that the ohmic current into the skin is a roughly rectangular pulse.
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Figure S4. Calmare output spectrogram showing the Fourier transform of Calmare
output colorimetrically over a 60 second period. The power amplitude is most intense
at the base frequency ~47 Hz) with harmonics of lesser intensity. RDPs are evident
as periods of constant base frequency. In each RDP the harmonics of the base
frequency have a unique set of intensities.
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Table S1. Exclusion criteria
Hospital Anxiety and
Depression Scale 1
MRI criteria
Maternity status
Neurological history
Allergies

Therapy history
1

Depression score above 15 (severe
depression)
Metal implants or claustrophobia
Pregnancy or breast feeding
History of epilepsy, brain damage, or
serious
psychiatric
disorder
(schizophrenia, etc)
Skin condition that would preclude
placement of electrodes
Neurolytic pain control devices such as
implanted spinal cord stimulators used
within one month of or during the study

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand.
1983;67(6):361-370.
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Sex

Age

Dx1

Yrs
Pain
Rx2

of

Table S2. One-treatment study subject characteristics
Verbal Pain Description Drugs

F

60+

I

10

T

F

30+

-

2

C

M

50+

D

20

C

F

50+

I

3

C

M

50+

I

10

T

M

M

50+

70+

I

6

I

10

C

T

F

60+

D

20+ T

M

50+

I

5-6

T

F

60+

I

15

C

F

70+

I

9

T

numbness and tingling, no burning pain
burning pain
Lyrica BID until 6 weeks ago
Ibuprofen PRN (800-1600 mg/day)
Flomax & Sudafed PRN.
stabbing pain up Achilles Lyrica BID for 2 w 1 yr ago
tendon
Gabapentin for 1 m 1.5 yr ago
Metanx BID
pain in bottom of feet and Gabapentin for a few m 4 yrs ago
toes
Oxycodone 30 mg TID
Tradjenta
Metformin
Aspirin 325 mg
Supplements
neuropathy both feet & Gabapentin 1 qPM for 3 m 1 yr ago
hands
no burning pain
Aspirin 81 mg
Advil PRN
numbness & tingling, mild Gabapentin for 1 m 1.5 yr ago
burning pain
Lyrica BID for 2 w 1 yr ago
Metanx BID
numbness and tingling, no Gabapentin 600 mg TID for multiple years
burning pain
until 4-6 w ago
Metformin 150 mg TID
numbness and tingling, no Gabapentin 5-7 pills daily until 3 y ago
burning pain
Sudafed PRN
Gabapentin 300 mg PRN, “took one last
week,”
600 mg TID for 1 w in 2006
Lyrica for several m. in 2006
Levothyroxin 137 mcg qd
burning only in feet
Topamax 50 mg qd
Sumatriptan PRN 100 mg for foot pain
Naproxen 100 mg BID
Celexa 40 mg qd
Flexeril 10 mg qd
Diphenhydramine (allergy) 25-75 mg qd
Valium 10 mg qd
Ambien 10 mg qd
27

F

60+ I

20

C

F

60+ R
S
D

11

T

60+ S

20+ C

M

50+ I

3

M

50+ D

10+ T

M

F

M

60+ C

60+ D

4

3

1Peripheral

C

T

C

numbness, tingling, and Oxycodone 300 mg q 4h for 3 d 2 m ago.
burning in both feet
Advil, ibuprofen PRN
Synthroid
Metformin 250 mg BID
Progesterone 100 mg BID
burning in upper forearms Neurontin trial 7 y ago
Excedrin PRN migraines
Topazepam PRN sleep
Atenolol 25 mg qd
lumbar pain L5-S1
sciatica bilateral into feet
pain mostly on lateral
sides of legs
pain in toes and balls of
feet
numbness & tingling in
both feet
no burning pain reported Gabapentin TID Oct 2014-Feb 2015
Lyrica 3-4 y ago
Insulin (short and long lasting)
Metformin
Drugs for acid reflux, high cholesterol, and
high blood pressure
numbness & tingling
Milxicam PRN pain
Tylenol 650 mg PRN pain
Peroxetine
Metformin
Glimeperide
Losartan
Claritin D 24-Hr
Multivitamin

Neuropathy Diagnosis – self-reported: I, idiopathic; D, diabetic; C,
Chemotherapy-induced; S, spinal injury; RSD, reflex sympathetic dystrophy;
2Treatment group: T, TENS; C, Calmare. Summary: Average female age was 59.1 (3571) years and average male age was 59.4 (51-70). 55.6% of the subjects reported an
idiopathic type of peripheral neuropathy, 22.2% reported diabetic, and 22.2% of the
subjects were distributed amongst chemotherapy-induced, spinal injury, RSD, and
undefined diagnoses. Pain duration ranged from 2 to over 20 years. Although the
intent was to gather subjects with burning pain in the extremities and with limited
anti-seizure pain med exposure, many of the subjects reported no pain, just
numbness and tingling upon arrival for the study.
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Yrs
Pain

Rx2

I

10

C

M 30+

D

17

T

M 50+

D

13

T

M 60+

I

20

T

13
10
4
5

C
T
T
T

3

T

2
8

T
C

Age

M 60+

Sex

Dx1

of

Table S3. Ten-treatment study subject characteristics
Verbal Pain Description

F 60+
M 30+
M 70+
M 60+

I
C
I
I

F
M
F
F

50+
60+
60+
30+

H
H
I
D

F

50+

D

F

60+

M 60+
M

D

12

5

3
15

I

-

50+
30+

I
C*

F

40+

S

60+

12

I
I

F
F
F

15
2
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1Peripheral

C
C
C
C

C

T
C

T
C

Dull ache in muscles, tender
pressure points, stabbing pain,
burning in feet
Feet keep getting tired, discomfort
walking on objects.
Burning
Feet started to feel pain and have
increased ever since
Shooting and deep, in feet and then
in thigh. A little bit in hands.
Pins and needles on surface of toes
and bottom of feet
Keeps him awake
Pins and needles, numbness and
tingling on feet
Begins in hands and spreads
Begins in feet
Pain in both feet and legs
Stinging,
hot
and
cold
simultaneously
Stinging, burning pain in toes and
feet.
Numb, sharp pain on toes. Cold, like
bugs crawling
Numb, sharp pain in toes
Burning Pain on feet, shins, and
hand
Feet and ankles
Left side all the way through arm
and back
Burning pain on tops and bottoms of
feet
Sharp, burning pain in left foot

Drugs

Gabapentin (not in 2
weeks)
Tramadol
weeks)

(not

in

2

Lyrica
Gabapentin (not in 2
weeks)
Gabapentin (not in 2
weeks)
Lyrica
Tramadol

Gabapentin

Neuropathy Diagnosis – self-reported: I, idiopathic; D, diabetic; C,
Chemotherapy-induced; C*, Chronic Regional Pain Syndrome; S, spinal injury; H,
Hereditary Sensory Neuropathy; RSD, reflex sympathetic dystrophy; 2Treatment
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group: T, TENS; C, Calmare. Summary: The average female age was 54.7 (36-68) years
and male age 58.5͙ (37-67) years. 50% of the subjects reported an idiopathic
diagnosis, 25% reported diabetic, and the other 25% were distributed amongst
chemotherapy-induced, spinal injury, CRPS, and hereditary diagnoses. Most subjects
had dealt with chronic pain for over 5 years, and the majority over 10 years. In this
ten-treatment study, more care was taken than in the preliminary study in prescreening the subjects for pain; also for medication use, although detail was only
gathered on anti-seizure or opioid analgesic medications. 60% reported never having
used anti-seizure or opioid analgesic medication. Twenty percent had terminated use
of gabapentin or tramadol two weeks prior to the study and the remaining 20%
terminated Lyrica, gabapentin or tramadol use 0-2 days prior to the study.
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Figure S5. Average intense pain (WNPS) ratings for ten-treatment study before first
treatment (after fMRI), after first treatment, and (before second treatment) next day
for A) Calmare group *P<0.01 (treatment effect, Post Tx (N=10) vs Pre Tx (N=8),
unpaired, one-tailed T test), B) TENS group (N=9) *P<0.01 (treatment effect, Post Tx
vs Pre Tx, paired, one-tailed T test). Error bars are ±2 S.E.M.
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Figure S6. Average subject Visual Analog Scale (VAS) pain ratings in mm for singletreatment study before treatment, after treatment, and next day for A) Calmare group
(N=9) *P<0.05 (treatment effect, Post Tx vs Pre Tx, paired, one-tailed T test), B) TENS
group (N=9) *P<0.01 (treatment effect, Post Tx vs Pre Tx, paired, one-tailed T test),
and C) Crossover group (N=8), *P<0.01 (treatment effect, Post Tx vs Pre Tx, paired,
one-tailed T test). Error bars are ±2 S.E.M.
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Figure S7. Average subject VAS pain ratings in mm for ten-treatment study before
first treatment (after fMRI), after first treatment, and (before second treatment) next
day for A) Calmare group *P<0.05 (treatment effect, Post Tx (N=10) vs Pre Tx (N=9),
unpaired, one-tailed T test), B) TENS group *P<0.05 (treatment effect, Post Tx (N=9)
vs Pre Tx (N=10), paired, one-tailed T test). Error bars are ±2 S.E.M.
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